News

Before joining PerkinElmer, Wilson was the corporate vice president of investor relations at Danaher Corporation (Danaher). At Danaher, he held key financial and business management positions. Wilson comes

“Rob’s leadership and deep understanding of PerkinElmer’s businesses, organization and entrepreneurial culture makes him ideally suited to lead the Company going forward,” said Summe. “I believe that PerkinElmer

Second Quarter Summary: Financial highlights: Operating income of $6.2 million Revenue by market: Therapeutic: Cardiovascular – $9.6 million Ophthalmology – $3.7 million Other Markets – $2.9 million Diagnostic

Scott Garrett, chairman, president and chief executive officer, said, Approximately 80% of our revenue is recurring, which continued to grow at 5% on a constant currency basis giving

Recurring income increased 22.2% to JPY46.4 billion. Net income decreased by 50% to JPY11.7 billion, as extraordinary losses of JPY21.5 billion were recorded due to valuation losses on

Swiss biopharmaceutical company Actelion has reported that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has issued a positive opinion

Centocor Ortho Biotech, a wholly-owned subsidiary of Johnson & Johnson, has received the FDA approval for its Simponi for the treatment of moderately to severely active rheumatoid arthritis,

Ridge Diagnostics, a neurodiagnostic company commercializing a proprietary blood test for depression or major depressive disorder, has received a Phase II, National Science Foundation, Small Business Innovation Research

2009 Outlook Looking forward to 2009, Bristol-Myers reaffirmed its GAAP per share earnings guidance of $1.58 – $1.73 and non-GAAP earnings outlook of $1.85 – $2.00 per share.